Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-01-27

Clinical Trial Update: Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating saracatinib in patients with unresectable stage III or stage IV melanoma; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Saracatinib (saracatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage IIA Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2014-01-27